These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 2252956)

  • 1. Lymphokine-activated killer (LAK) cell purging of leukemic bone marrow: range of activity against different hematopoietic neoplasms.
    Long GS; Cramer DV; Harnaha JB; Hiserodt JC
    Bone Marrow Transplant; 1990 Sep; 6(3):169-77. PubMed ID: 2252956
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lymphokine-activated killer (LAK) cell purging of bone marrow.
    Cramer DV; Long GS
    Prog Clin Biol Res; 1990; 333():125-35; discussion 136-7. PubMed ID: 2308977
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lymphokine-activated killer cell purging of leukemia cells from bone marrow prior to syngeneic transplantation.
    Long GS; Hiserodt JC; Harnaha JB; Cramer DV
    Transplantation; 1988 Sep; 46(3):433-8. PubMed ID: 2901797
    [TBL] [Abstract][Full Text] [Related]  

  • 4. VLA-6 (CDw49f) is an important adhesion molecule in NK cell-mediated cytotoxicity following autologous or allogeneic bone marrow transplantation.
    Lowdell MW; Shamim F; Hamon M; Macdonald ID; Prentice HG
    Exp Hematol; 1995 Dec; 23(14):1530-4. PubMed ID: 8542943
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel approach to purging of leukemia by activation of bone marrow with interleukin 2.
    Charak BS; Malloy B; Agah R; Mazumder A
    Bone Marrow Transplant; 1990 Sep; 6(3):193-8. PubMed ID: 2252959
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of lymphokine-activated killer cells to prevent bone marrow graft rejection and lethal graft-vs-host disease.
    Azuma E; Yamamoto H; Kaplan J
    J Immunol; 1989 Sep; 143(5):1524-9. PubMed ID: 2668409
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design and validation of a clinically applicable culture procedure for the generation of interleukin-2 activated natural killer cells in human bone marrow autografts.
    Klingemann HG; Deal H; Reid D; Eaves CJ
    Exp Hematol; 1993 Aug; 21(9):1263-70. PubMed ID: 8330650
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential of autologous immunologic effector cells for bone marrow purging in patients with chronic myeloid leukemia.
    Scheffold C; Brandt K; Johnston V; Lefterova P; Degen B; Schöntube M; Huhn D; Neubauer A; Schmidt-Wolf IG
    Bone Marrow Transplant; 1995 Jan; 15(1):33-9. PubMed ID: 7538001
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Natural killer and lymphokine-activated killer cell activities from human marrow precursors. II. The effects of IL-3 and IL-4.
    Keever CA; Pekle K; Gazzola MV; Collins NH; Bourhis JH; Gillio A
    J Immunol; 1989 Nov; 143(10):3241-9. PubMed ID: 2809200
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LAK cell purging of bone marrow: lack of effect on reconstitution and in vitro GM-CFU colony formation.
    Long GS; Cramer DV
    Transplant Proc; 1989 Apr; 21(2):3277-8. PubMed ID: 2652814
    [No Abstract]   [Full Text] [Related]  

  • 11. In vitro resistance of the brown Norway rat acute myelocytic leukemia (BNML) to lymphokine-activated killer activity.
    Gaiser JF; Kloosterman TC; Martens AC; Hagenbeek A
    Leukemia; 1993 May; 7(5):736-41. PubMed ID: 8483327
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful engraftment after autologous transplantation of 10-day cultured bone marrow activated by interleukin 2 in patients with acute lymphoblastic leukemia.
    Beaujean F; Bernaudin F; Kuentz M; Lemerle S; Cordonnier C; Le Forestier C; Reinert P; Duedari N; Brandely M; Vernant JP
    Bone Marrow Transplant; 1995 May; 15(5):691-6. PubMed ID: 7670397
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lymphokine-activated killer cells in rats: analysis of tissue and strain distribution, ontogeny, and target specificity.
    Vujanovic NL; Herberman RB; Hiserodt JC
    Cancer Res; 1988 Feb; 48(4):878-83. PubMed ID: 3257411
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Spontaneous alloreactivity of natural killer (NK) and lymphokine-activated killer (LAK) cells from athymic rats against normal haemic cells. NK cells stimulate syngeneic but inhibit allogeneic haemopoiesis.
    Rolstad B; Benestad HB
    Immunology; 1991 Sep; 74(1):86-93. PubMed ID: 1937576
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: direct correlation between reduction of established metastases and cytolytic activity of lymphokine-activated killer cells.
    Mulé JJ; Yang J; Shu S; Rosenberg SA
    J Immunol; 1986 May; 136(10):3899-909. PubMed ID: 2871106
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autologous bone marrow purging by in situ IL-2 activation of endogenous killer cells.
    Margolin KA; Wright C; Forman SJ
    Leukemia; 1997 May; 11(5):723-8. PubMed ID: 9180298
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro LAK (lymphokine activated killer) activity following autologous peripheral blood stem cell is significantly greater than that following autologous bone marrow and allogeneic bone marrow transplantation.
    Fegan C; Thomas H; Bailey-Wood R; Coleman S; Phillips S; Hoy T; Whittaker JA
    Bone Marrow Transplant; 1995 Aug; 16(2):277-81. PubMed ID: 7581148
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Generation of lymphokine-activated killer (LAK) cells and possible implications in autologous bone marrow transplantation--a preliminary report.
    Tzeng CH; Chuang MW; Wang SY; Hsieh RK; Liu CJ; Fan S; Chen PM
    Proc Natl Sci Counc Repub China B; 1990 Jan; 14(1):47-53. PubMed ID: 2381997
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination of interleukin-2-stimulated lymphocytes and bispecific antibodies that efficiently lyse leukemic cells does not affect bone marrow CD34-positive stem cell function in vitro.
    Kaneko T; Fukuda J; Teramura M; Fusauchi Y; Kakui Y; Okumura K; Mizoguchi H; Oshimi K
    Bone Marrow Transplant; 1994 Aug; 14(2):213-7. PubMed ID: 7527685
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lymphokine-activated killer cells selectively kill tumor cells in bone marrow without compromising bone marrow stem cell function in vitro.
    van den Brink MR; Voogt PJ; Marijt WA; van Luxemburg-Heys SA; van Rood JJ; Brand A
    Blood; 1989 Jul; 74(1):354-60. PubMed ID: 2787676
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.